

## Could you help shape our research into targeted treatments for lymphoma?

# REMoDL-A

### What are we doing?

Diffuse large B cell lymphoma (DLBCL) is an aggressive form non-Hodgkin lymphoma. Standard first-line treatment is a combination of chemotherapy drugs called R-CHOP, which works well for many people, but some patients will not see a response or may see their lymphoma come back. The REMoDL-A trial is testing whether adding a targeted cancer drug called acalabrutinib to standard chemotherapy could be a more effective treatment for patients, depending on the genetic profile of their individual cancer.

### How can you help?

Are you a patient, carer or family member with experience of DLBCL or another lymphoma? We're looking for a public contributor to sit on our Trial Management Group (TMG). The TMG has general oversight for how a trial is run and ensures that it is meeting the requirements of the trial protocol and is acceptable to the patients taking part.

This role will involve:

- Meeting every 3-4 months via video call (Microsoft Teams) to help provide a patient insight into any issues that arise in the oversight of the trial.
- Reading any documents and TMG reports prior to meetings.
- Reading and reviewing patient-facing documents such as Participant Information Sheets and Consent Forms.

### How will we support you?

The trial management team will give you an initial overview of the project and support you throughout your role. There will also be wider support and resources available from our PPI coordinator and our local network of public involvement professionals and contributors. You will be reimbursed for your time in line with [NIHR guidelines](#).

**If you are interested in this role or have any other questions, please email Nicole Keyworth, Senior Trial Manager – [remodla@soton.ac.uk](mailto:remodla@soton.ac.uk)**